Lipid Response to Keto and the Role of Glycation in Atherosclerosis
Introduction
Cardiovascular disease (CVD) is primarily driven by atherosclerosis, the buildup of plaque in arterial walls. While LDL cholesterol has long been targeted as a risk factor, emerging evidence shows that glycation, particularly due to high sugar intake, may be a more critical driver. This document reviews the biochemical links between sugar, glycation, and CVD, and examines how a ketogenic diet alters blood lipids—especially in people classified as hyper-responders.
Sugar, Glycation, and Atherosclerosis
What Is Glycation?
Glycation is a non-enzymatic reaction where sugars (mainly glucose) bind to proteins or lipids, forming advanced glycation end products (AGEs).
- Alters protein/lipid structure and function
- Increases oxidative stress and inflammation
- Stiffens blood vessels and damages endothelial cells
Glycation Cascade Leading to Atherosclerosis
- High sugar intake → elevated blood glucose
- Glucose binds to LDL particles → glycated LDL
- Glycated LDL becomes more susceptible to oxidation
- These modified particles are taken up by immune cells → foam cell formation
- Foam cells accumulate in arterial walls → plaque and atherosclerosis
Summary Flow:
High Sugar → High Glucose → LDL Glycation → Oxidation + Foam Cells → Atherosclerosis
Even with normal LDL levels, glycation transforms LDL into atherogenic particles, making sugar intake a critical modifiable risk factor.
Saturated Fat and Its Contextual Impact
Key Points
- Saturated fat can raise LDL-C, but the effect depends on:
- Individual metabolic state
- What macronutrient it replaces (e.g., refined carbs vs. unsaturated fats)
- In a low-sugar environment (e.g., keto), LDL is less likely to be glycated or oxidized
- Saturated fats may have a neutral or even favorable impact when consumed in a low-carb, high-fat diet without refined sugars
Effects of the Ketogenic Diet on Lipids
General Trends on Keto
| Marker | Typical Change on Keto |
|---|---|
| LDL-C | Often increases (varies) |
| HDL-C | Increases |
| Triglycerides | Decreases |
| Trig/HDL Ratio | Improves (lowers) |
| Glucose/Insulin | Decrease |
| Inflammation | May decrease (e.g., CRP) |
- Removing sugar reduces glycation, a major CVD driver
- Triglyceride/HDL ratio, a strong insulin sensitivity marker, typically improves significantly
Hyper-Responders to Keto
Who Are Hyper-Responders?
Hyper-responders exhibit unusually large increases in LDL-C (often >50–100%) after switching to a ketogenic or low-carb diet. Often seen in:
- Lean individuals
- Metabolically healthy, low-insulin states
- High physical activity levels
Estimated Changes for Hyper-Responders (Day 35–42)
| Lipid Marker | Pre-Keto Estimate | Hyper-Responder Estimate |
|---|---|---|
| LDL-C | ~2.5 mmol/L | 4.5–6.5+ mmol/L |
| Total Cholesterol | ~4.4 mmol/L | 6.5–8.5+ mmol/L |
| HDL-C | ~1.5 mmol/L | 1.6–2.0 mmol/L |
| Triglycerides | ~0.8 mmol/L | 0.4–0.7 mmol/L |
| Trig/HDL Ratio | ~0.52 | 0.2–0.4 |
These changes often occur within 4–6 weeks and are usually accompanied by low inflammation, low insulin, and favorable HDL/triglyceride levels.
Risk Considerations
- Elevated ApoB or LDL particle count (LDL-P) may warrant further evaluation
- Risk must be interpreted in context: glycation, oxidation, and inflammation matter more than LDL-C alone
Bottom Line
- Sugar-driven glycation is a major contributor to atherosclerosis—more so than saturated fat in many cases
- In a ketogenic context (no sugar, low insulin), saturated fat may be metabolically neutral or beneficial
- Hyper-responders to keto may see large LDL increases, but often with favorable markers elsewhere
- True risk requires a comprehensive lipid profile, including ApoB, LDL-P, and inflammatory markers like CRP
References
[1] Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am J Clin Nutr. 2010;91(3):535–546.
[2] Goldberg IJ, Trent CM, Schulze PC. Lipoprotein metabolism and cardiovascular disease. Nat Rev Cardiol. 2012;9(10):570–582.
[3] Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–1625.
[4] Norwitz NG, Feldman D, Lustig RH. Lean mass hyper-responder phenotype presents a paradox for the lipid hypothesis of cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2021;28(5):334–342.
[5] Ludwig DS, Willett WC, Volek JS, Neuhouser ML. Dietary fat: From foe to friend? Science. 2018;362(6416):764–770.